ARWR vs IONS: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ARWR and IONS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ARWR and IONS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Arrowhead Pharmaceuticals is a biopharmaceutical company built around RNA interference (RNAi), using its TRiM (Targeted RNAi Molecule) platform to design small interfering RNA (siRNA) medicines that silence disease-causing genes in the liver and, increasingly, in tissues like the lung and muscle. Its lead drug, plozasiran (marketed as REDEMPLO), targets APOC3 to lower triglycerides and was approved by the U.S. FDA in November 2025 for familial chylomicronemia syndrome (FCS), with additional approvals in China, Canada, Australia, and the European Union. Behind it sits a broad pipeline spanning cardiometabolic disease, obesity, pulmonary, CNS, and muscle targets, several of which are partnered.

Full ARWR guide

Ionis Pharmaceuticals is a California-based biotechnology company that invented and commercialized antisense technology, a way to design short strands of nucleic acid that silence or modify the RNA behind disease-causing proteins. For decades it operated largely as an R&D and royalty engine, partnering drugs like Spinraza (spinal muscular atrophy, with Biogen) and Wainua (hereditary ATTR polyneuropathy, with AstraZeneca) to larger companies. It now markets around seven medicines and, starting in 2025, launched its first fully owned products, Tryngolza (olezarsen) for familial chylomicronemia syndrome and Dawnzera for hereditary angioedema.

Full IONS guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ARWR drivers: REDEMPLO (plozasiran) launch and label expansion; Partnership economics.
• IONS drivers: Owned commercial launches; Olezarsen label expansion.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Arrowhead remains fundamentally a pipeline and partnership story, so revenue is lumpy and heavily dependent on milestone payments that do not recur each quarter, and the company posts operating losses in periods without such payments. For IONS, ionis still operates at a loss, with 2026 non-GAAP operating loss guidance in the range of roughly $425 million to $475 million, so profitability remains unproven.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ARWR if you believe its drivers more; IONS if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ARWR and IONS guides.

ARWR. Arrowhead's reported revenue is dominated by partnership and milestone payments, which makes results swing dramatically between quarters (a large Q1 FY2026 milestone quarter versus a much smaller Q2). Traditional valuation multiples are of limited use for a company at this stage, so investors tend to focus on the REDEMPLO launch trajectory, pipeline readouts, cash runway, and deal flow rather than trailing earnings.

IONS. Ionis trades as a growth-stage biotech, valued on future product sales rather than current earnings since it remains unprofitable. Revenue is accelerating on owned launches and milestone payments, and management raised full-year 2026 guidance after a strong first quarter. The valuation embeds significant expectations for olezarsen's expansion and the broader pipeline.

Headline figures (approximate, JULY 2026): ARWR shows revenue (fy2025, ended sept 2025) ~$829M, q1 fy2026 revenue (oct-dec 2025) ~$264M, q2 fy2026 revenue (jan-mar 2026) ~$74M, total cash resources (early 2026) ~$1.78B; IONS shows market cap ~$14B, revenue (2025) ~$944M, q1 2026 revenue ~$246M (up ~87% YoY), 2026 revenue guidance ~$875M-$900M.

ARWR and IONS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ARWR and IONS exposure against your real portfolio. It is not an investment adviser.